Lung Cancer

The global morbidity rate from lung cancer is on the rise.  Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancersand the treatment has become increasingly complex.  Most lung carcinomas are diagnosed at an advanced stage, conferring a poor prognosis. 

Therefore, there is an urgent need for better biomarkers and more effective local treatments. The focus of the TAU research groups is to further understand the metastatic nature of the cancer cells in order to reduce the disease progression.